TNFα antagonists are the longest-used biologic agents in the treatment of psoriasis; they are also widely used in the treatment of other immune-mediated diseases, such as psoriatic (PsA) and other seronegative arthropathies (SA), rheumatic arthritis (RA), inflammatory bowel diseases (IBD), hidradenitis suppurativa (HS), or uveitis, in some indications also in children [46]. This evidence concerns the gene TNF and inflammatory bowel disease.